Literature DB >> 9389860

Spontaneous movements associated with rocuronium: is pain on injection the cause?

A Borgeat1, D Kwiatkowski.   

Abstract

Spontaneous movements are sometimes observed of the arm into which rocuronium is administered. In order to assess a possible relationship between these movements and pain, we injected in 10 awake, ASA I patients, in a double-blind manner, both rocuronium 1 ml (10 mg) and 0.9% NaCI 1 ml (placebo), with a 30-s interval in between. None of the patients receiving placebo complained of pain, but eight of 10 patients reported a strong burning pain during injection of rocuronium with brisk flexion of the elbow and wrist, similar to those observed in patients after induction of anaesthesia. A second injection of rocuronium did not produce such pain and no movements were observed. We conclude that injection of rocuronium is associated with severe, burning pain of short duration, responsible for the spontaneous movements in the arm observed after induction of anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389860     DOI: 10.1093/bja/79.3.382

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  45 in total

1.  Availability of a 5% lidocaine patch used prophylactically for venipuncture- or injection-related pain in children.

Authors:  Cheul-Hong Kim; Ji-Uk Yoon; Hyeon-Jung Lee; Sang-Wook Shin; Ji-Young Yoon; Gyeong-Jo Byeon
Journal:  J Anesth       Date:  2012-03-09       Impact factor: 2.078

Review 2.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Effect of narcotic pretreatment on pain after rocuronium injection: a randomized, double-blind controlled comparison with lidocaine.

Authors:  Mukta Singh; Himanshu Chauhan; Girija P Rath; Hemanshu Prabhakar; Parmod K Bithal; Hari H Dash
Journal:  J Anesth       Date:  2007-11-01       Impact factor: 2.078

4.  Comparison of randomized preemptive dexketoprofen trometamol or placebo tablets to prevent withdrawal movement caused by rocuronium injection.

Authors:  Gözde Bumin Aydın; Reyhan Polat; Julide Ergil; Murat Sayın; Ceyda Ozhan Caparlar
Journal:  J Anesth       Date:  2013-11-08       Impact factor: 2.078

5.  Pretreatment with remifentanil, fentanyl, or lidocaine to prevent withdrawal after rocuronium using venous occlusion technique in children and adolescents: a prospective randomized placebo-controlled double-blind study.

Authors:  S A Abu-Halaweh; A K Aloweidi; I Y Qudaisat; M O Al-Hussami; K R Al Zaben; A S Abu-Halaweh
Journal:  J Anesth       Date:  2014-05-11       Impact factor: 2.078

6.  Combination of nitrous oxide and lidocaine to prevent withdrawal after rocuronium in children.

Authors:  Hyun-Jeong Kwak; Yun Jeong Chae; Sook Young Lee; Young Jun Kim; Jong-Yeop Kim
Journal:  Korean J Anesthesiol       Date:  2010-05-29

7.  The influence of age and gender on remifentanil EC(50) for preventing rocuronium induced withdrawal movements.

Authors:  So Jin Park; Hye Jin Park; Ju Youn Choi; Hyo Seok Kang; Hong Seok Choi
Journal:  Korean J Anesthesiol       Date:  2010-03-29

8.  Effect of nitrous oxide on pain due to rocuronium injection: A randomised, double-blind, controlled clinical trial.

Authors:  Sonal Sharma; Deepak Sharma; Ashish Jain; Anjali Jain
Journal:  Indian J Anaesth       Date:  2010-03

9.  Effect of pretreatment with acetaminophen on withdrawal movements associated with injection of rocuronium: a prospective, randomized, double-blind, placebo controlled study.

Authors:  Younghoon Jeon; Sung-Uk Baek; Sung Sik Park; Si Oh Kim; Woon-Yi Baek; Jin-Seok Yeo
Journal:  Korean J Anesthesiol       Date:  2010-07-21

10.  Antihistamine pretreatment to reduce incidence of withdrawal movement after rocuronium injection.

Authors:  Ho Jun Lee; Sung Jin Han; Heezoo Kim; Il Ok Lee; Myoung Hoon Kong; Nan Suk Kim; Sang Ho Lim; Mi Kyoung Lee
Journal:  J Korean Med Sci       Date:  2009-09-24       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.